SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-228378
Filing Date
2020-08-24
Accepted
2020-08-24 16:21:42
Documents
13
Period of Report
2020-08-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d36717d8k.htm   iXBRL 8-K 28109
2 EX-10.1 d36717dex101.htm EX-10.1 71373
  Complete submission text file 0001193125-20-228378.txt   246656

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cue-20200821.xsd EX-101.SCH 3079
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cue-20200821_lab.xml EX-101.LAB 18123
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cue-20200821_pre.xml EX-101.PRE 11412
6 EXTRACTED XBRL INSTANCE DOCUMENT d36717d8k_htm.xml XML 3337
Mailing Address 21 ERIE STREET CAMBRIDGE MA 02139
Business Address 21 ERIE STREET CAMBRIDGE MA 02139 617-949-2680
Cue Biopharma, Inc. (Filer) CIK: 0001645460 (see all company filings)

IRS No.: 473324577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38327 | Film No.: 201128108
SIC: 2834 Pharmaceutical Preparations